It's About Time! Timing in Epilepsy Evaluation and Treatment
- PMID: 39554272
- PMCID: PMC11561932
- DOI: 10.1177/15357597241238072
It's About Time! Timing in Epilepsy Evaluation and Treatment
Abstract
The 2023 American Epilepsy Society Annual Course "It's About Time" addressed timing in epilepsy evaluation and treatment with respect to health disparity and vulnerable populations and diagnostic, clinical, and epilepsy surgery evaluation. This comprehensive course included topics on gaps in epilepsy care and optimization of behavioral health for patients with epilepsy. The summary details current knowledge in areas of seizure forecasting and epileptogenesis. Intricacies and controversies over timing were discussed for treatment of nonconvulsive seizures and ictal-interictal patterns, acute symptomatic seizures, neuromodulation versus surgery, and epilepsy surgery in status epilepticus. Timing regarding clinical care in autoimmune-associated epilepsy, developmental and epileptic encephalopathy, and dietary therapy were examined. Additionally, salient topics on using novel biomarkers and collaboration with neuropsychological outcomes were also tackled in this all-encompassing lecture series.
Keywords: AES; annual course; behavioral health; disparities; epilepsy; ictal-interictal continuum; ketogenic diet therapy; seizure; time; timing.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. DC reports funding from Neurelis Pharmaceuticals for consultation. ET reports personal fees from EVER Pharma, Marinus, Arvelle, Angelini, Argenx, Medtronic, Biocodex Bial-Portela & Ca, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, Epilog, UCB, Biogen, Sanofi, Jazz Pharmaceuticals, and Actavis. His institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Osterreichischer Fond zur Wissenschaftsforderung, Bundesministerium fu¨r Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank. CR received speaker fees from Marinus for education content development, consulting fees from Quattro Consulting, and consulting fees from Azurity Pharmaceutical for advisory committee.
References
-
- Burneo JG, Jette N, Theodore W, et al. Task Force on Disparities in Epilepsy Care; North American Commission of the International League Against Epilepsy.Disparities in epilepsy: report of a systematic review by the North American Commission of the International League Against Epilepsy. Epilepsia. 2009;50(10):2285–2295. doi:10.1111/j.1528-1167.2009.02282.x. PMID: 19732134; PMCID: PMC3181115. - PMC - PubMed
-
- Wilmshurst JM, Catsman-Berrevoets C, Gilbert DL, et al. Pediatric Neurology Training Study Group. Access to pediatric neurology training and services worldwide: a survey by the International Child Neurology Association. Neurology. 2023;101(18):798–808. doi:10.1212/WNL.0000000000207633. PMID: 37491325; PMCID: PMC10634651. - PMC - PubMed
-
- Kandregula S, Terrell D, Beyl R, et al. Racial and socioeconomic disparities in the advanced treatment of medically intractable pediatric epilepsy. Neurosurg Focus. 2022;53(4): E2. doi:10.3171/2022.7.FOCUS22338. PMID: 36183182. - PubMed
-
- International League Against Epilepsy. Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031. Geneva: World Health Organization; 2023. https://www.ilae.org/about-ilae/how-the-ilae-works/policy-and-advocacy/i...
Publication types
LinkOut - more resources
Full Text Sources
